Herion addicts infected by HBV and HIV have a low prevalence of HBV DNA in peripheral blood mononuclear cells

Delfini, C.; Garbuglia, Anna Rosa; Alfani, Elena; Di, Antonino; Sette, P; Benedetto, A.

doi:10.1002/jmv.1890410206

Cited by 7 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 Most of the more recent publications are cited here. [9][10][11][12][13][14][15][18][19][20][21][22][23][24][25][26] Considering this apparently overwhelming evidence, the question must be raised why we present a report in which we claim that the opposite is true. As we will show in the following, our data are consistent with what has of an HBV-transgenic and a nontransgenic mouse.…”

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus

et al. 1996

View full text Add to dashboard Cite

There have been numerous reports suggesting that human peripheral blood mononuclear cells (PBMCs) can be productively infected with human hepatitis B virus (HBV). We therefore examined whether the PBMCs can be used to establish an in vitro infection system for HBV. Freshly purified PBMCs were incubated with HBV with or without mitogen stimulation. Successful infection was tested using a newly developed PCR method that can differentiate between the relaxed circular (RC) DNA of the virus inoculum and the covalently closed circular (CCC) DNA which is formed only after successful virus entry. This method enables virus uptake to be proven even if the infection is abortive because there is no gene expression because of the lack of liver specific gene expression factors. All attempts to detect CCC DNA after incubation of PBMCs with HBV failed. On the contrary, CCC DNA could easily be detected in infected liver or after in vitro infection of primary human hepatocytes. Because this result appeared to be contradictory to the published data, we analyzed PMBCs isolated from infected patients. We could confirm that HBV DNA and RNA are associated with these cells. However, even after restimulation with mitogens, we could only detect RC DNA. Moreover, we could also demonstrate that viral RNA is present in free virus. Apparently, a certain amount of defective particles do not reverse transcribe the packaged pregenomic RNA. In summary we found no evidence that PMBCs can be infected with HBV and conclude that all previous observations can be explained by adsorbed virus.

show abstract

Section: Discussionmentioning

confidence: 99%

Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus

et al. 1996

View full text Add to dashboard Cite

show abstract

“…The replicative cycle of HBV DNA shows that HBV RNA exists in cells and detecting HBV RNA in serum is difficult. In the early 1990s, some studies reported the detection of HBV RNA in peripheral blood mononuclear cells of patients infected with HBV[ 51 - 54 ]. However, it was until 1996 that Köck et al[ 55 ] reported the detection of HBV RNA in peripheral blood virions of patients with chronic HBV infection using the reverse transcription PCR method.…”

Section: Hbv Rna Level In Peripheral Bloodmentioning

confidence: 99%

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA

Liu

Liang

2018

WJH

View full text Add to dashboard Cite

As alternative indexes of hepatitis B virus (HBV), covalently closed circular DNA (cccDNA) transcriptional activity, hepatitis B surface antigen (HBsAg), hepatitis B core-related antigen (HBcrAg), and peripheral blood RNA known as pgRNA, have been advocated as novel serum markers for prediction of prognosis and treatment response in chronic hepatitis B (CHB). Since the availability of commercial quantitative assays of HBsAg in 2011, HBsAg has been widely used for predicting treatment response of patients with CHB. Patients who received interferon therapy have shown a sharper reduction of HBsAg level than those who received nucleoside drug (NAs) therapy. Upon peginterferon treatment, sustained responders have presented a larger reduction of HBsAg level than the non-responders. An absence of HBsAg decline, together with < 2log reduction in HBV DNA at week 12, can serve as a stopping rule in HBsAg-negative patients infected with genotype D HBV. A sharp reduction of HBsAg titer in the NAs therapy is a predictor of HBsAg clearance in long-term treatment. HBcrAg, which consists of three species of related proteins sharing an identical 149 amino acid sequence, including HbcAg, hepatitis B e antigen (HBeAg), and a truncated 22-kDa precore protein, is still detectable in situations where serum HBV DNA levels become undetectable or HBsAg loss is achieved. Therefore, HBcrAg remains a measurable serum marker to correlate with cccDNA in this situation. The decline in HBcrAg has been observed with NAs therapy and the pattern of decline might provide prognostic information on the risk of HBV post-treatment reactivation. Peripheral blood RNA, which is known as pgRNA, directly derives from cccDNA and reflects intrahepatic cccDNA level. Quantitative pgRNA has been suggested to be helpful in CHB management. However, commercial quantitative assays are lacking. Additionally, the use of simultaneous and continuous clearance of HBV RNA and HBV DNA in serum has been suggested to be a safe stopping rule of NAs therapy for patients with CHB. However, clinical studies of large sample sizes are needed to prove the feasibility and significance of using serum HBV RNA as the assessment standard of antiviral therapy in CHB and the safety of the stopping rule in clinics.

show abstract

“…36 Single point mutations in the genome of this virus may significantly alter its antigenicity and complicate serological testing. 36 Single point mutations in the genome of this virus may significantly alter its antigenicity and complicate serological testing.…”

Section: Diagnosis Of Fetal Infectionsmentioning

confidence: 99%

Polymerase chain reaction and its use in obstetrics

Overton

Lighten

Bennett

1995

Fet. Matern. Med. Rev.

View full text Add to dashboard Cite

Deoxyribonucleic acid (DNA) is composed of a deoxyribose backbone, the three position (3') of each deoxyribose being linked to the five position (5') of the next by a phosphodiester bond. At the two position each deoxyribose is linked to one of four nucleic acids; the purines adenine or guanine or the pyrimadines thymine or cytosine. Each DNA molecule is made up of two such strands in a double helix with the nucleic acid bases on the inside. The bases pair by hydrogen bonding, adenine (A) with thymine (T) and cytosine (C) with guanine (G). Deoxyribonucleic acid is replicated by separation of the two strands and synthesis by DNA polymerases of new complementary strands. With one notable exception, the reverse transcriptase produced by viruses, DNA polymerases always add new bases at the 3' end of the molecule. Ribonucleic acid (RNA) has a structure similar to that of DNA but is always single stranded. The backbone consists of ribose, and uracil is used in place of thymine.

show abstract

Herion addicts infected by HBV and HIV have a low prevalence of HBV DNA in peripheral blood mononuclear cells

Cited by 7 publications

References 29 publications

Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus

Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus

Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA

Polymerase chain reaction and its use in obstetrics

Contact Info

Product

Resources

About